Sai Parenteral’s IPO: Issue subscribed just 4% on day 1. Check price band, GMP
Why it matters: Sai Parenteral's IPO flop highlights investor skepticism over valuations, even for growth-oriented companies.
- Sai Parenteral's IPO was subscribed only 4% on its first day, indicating very weak initial demand.
- Institutional investors completely avoided the IPO, while retail and NII interest remained low.
- Valuations for Sai Parenteral are seen as expensive, contributing to cautious investor sentiment despite the company's strong growth and expansion plans.
- Grey market premium (GMP) for the IPO was nonexistent, further dampening investor enthusiasm.
Sai Parenteral's IPO saw a dismal 4% subscription on its opening day, with institutional investors notably absent and retail interest remaining low. Despite the company's growth and expansion plans, investor caution is driven by perceived expensive valuations and a lack of grey market premium. This weak demand signals a challenging market reception for the new offering.
